Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms by Histologic Type 1Meningioma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Familial ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

venetoclax 6Azacitidine 6Cytarabine 5fludarabine 4Methotrexate 3fludarabine phosphate 2aldesleukin 2RO6839921 2Mitoxantrone 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Decitabine 2Dasatinib 2zileuton 1thymoglobulin 1spartalizumab 1sabatolimab 1quizartinib 1pulrodemstat besilate 1posaconazole 1plerixafor 1gilteritinib 1etoposide phosphate 1emvododstat 1daratumumab 1blinatumomab 1Sorafenib 1Sirolimus 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡